Other
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation
Humana Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation decreased by 44.3% to $751M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 63.0%, from $2.03B to $751M.
Analysis
StatementIncome Statement
SectionOther
First reportedQ3 2022
Last reportedQ1 2026Apr 29, 2026
Metric ID:
other_cash_cash_equivalents_restricted_cash_and_restrict_8b4577Historical Data
7 periods
| Q3 '22 | Q1 '23 | Q2 '23 | Q1 '24 | Q1 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|
| Value | $8.34B | $8.67B | $2.48B | $1.22B | $2.03B | $1.35B | $751M |
| QoQ Change | — | +4.0% | -71.4% | -50.9% | +66.9% | -33.6% | -44.3% |
| YoY Change | — | — | — | -86.0% | +66.9% | — | -63.0% |
Range$751M – $8.67B
CAGR-79.9%
Avg YoY Growth-27.4%
Median YoY Growth-63.0%
Current Streak2 quarters decline
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation at Other Companies
Frequently Asked Questions
- What is Humana's cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation?
- Humana (HUM) reported cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation of $751M in Q1 2026.
- How has Humana's cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation changed year-over-year?
- Humana's cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation decreased by 63.0% year-over-year, from $2.03B to $751M.